论文部分内容阅读
目的：研究“双弹头”导向治疗原发性肝癌毒副反应。方法：用１３１Ｉ－抗ＡＦＰ－ＭＭＣ“双弹头”导向治疗原发性肝癌２９例（５４例次），用自身对照设计（单组比较设计），全组１３１Ｉ－平均治疗剂量为６２．０９×１０７Ｂｑ，（２１．５３～１４９．１１）×１０７Ｂｑ。结果：治疗后外周血象无明显变化，心和肾功能正常，肝功能ＡＬＴ有７例轻度升高；甲状腺功能Ｔ３、Ｔ４值下降分别有３例和１例，过敏反应出现３例。结论：本组治疗耐受性良好，毒副反应轻微。
Objective: To study the side effects of “double warheads” in the treatment of primary liver cancer. METHODS: Twenty-nine cases (54 cases) of primary hepatocellular carcinoma were treated with 131I-anti-AFP-MMC “Double Warheads”. Using self-control design (single-group comparative design), the whole group 131I-average therapeutic dose was 62.09 × 107Bq, (21.53 ~ 149.11) × 107Bq. RESULTS: There was no significant change in peripheral blood counts after treatment, and heart and kidney function were normal. There were 7 cases of mild liver function ALT elevation; thyroid function T3 and T4 values decreased in 3 cases and 1 case respectively, and allergic reaction occurred in 3 cases. Conclusion: The treatment of this group is well tolerated and has slight side effects.